GeneLink names new CEO
This article was originally published in Clinica
Gary Beeman has been appointed CEO and president of consumer genomics specialist GeneLink BioSciences. He replaces interim CEO David Macdonald, who will continue to work with GeneLink (Longwood, Florida) in a consulting capacity. Most recently, Mr Beeman was CEO and founder of Bay Hill Ventures, a private capital firm. He has also served as strategic planning director for GeneLink’s board, and director of marketing communications for GeneWize Life Sciences, a subsidiary of GeneLink. Meanwhile, Sharon Tahaney has been named president of GeneWize. She was previously senior vice-president of sales and marketing at the company.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.